Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7822610 | 0.82 | CTSK (0.33) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL6039782 | 0.81 | DGAT1 (0.35) | DGAT1CA1CA2CA7CA12 | |
| SCHEMBL14922218 | 0.80 | — | — | |
| SCHEMBL6624042 | 0.80 | CA1 (0.43) | CA1CA2CA7CA12CA14 | |
| SCHEMBL1278864 | 0.80 | PTPRC (0.33) | CA1CA2CA7CA12CA14 | |
| SCHEMBL16967740 | 0.80 | MEN1 (0.33) | CA1CA2CA7KMT2ACTSK | |
| SCHEMBL3177194 | 0.80 | MEN1 (0.33) | CA1CA2CA7KMT2ACTSK | |
| SCHEMBL3161545 | 0.80 | MEN1 (0.33) | CA1CA2CA7KMT2ACTSK | |
| SCHEMBL6977014 | 0.78 | CYP2D6 (0.33) | CA1CA2CA7CTSK | |
| SCHEMBL3174619 | 0.78 | CA12 (0.41) | DGAT1CA2CA12CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086255-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | Mutabilis (FR) | 2022-11-09 | — | — | EP | disclosed |
| EP-3519411-B1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2022-06-22 | — | — | EP | disclosed |
| CN-113929680-A | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2022-01-14 | — | — | CN | disclosed |
| CN-109906226-B | Heterocyclic compounds and their use in the prevention or treatment of bacterial infections | 拜欧蒂姆公司 | 2021-11-02 | — | — | CN | disclosed |
| US-10722520-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | MUTABILIS (FR) | 2020-07-28 | — | — | US | disclosed |
| US-20190224210-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | MUTABILIS (FR) | 2019-07-25 | — | — | US | disclosed |
| US-9309211-B2 | Arylalkene derivatives and use thereof as selective estrogen receptor modulators | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2016-04-12 | — | — | US | disclosed |
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| CN-101374846-B | Cytotoxic agents containing novel tomaymycin derivatives and their therapeutic use | SANOFI AVENTIS | 2013-10-30 | — | — | CN | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| CN-101374846-A | Cytotoxic agents containing novel tomaymycin derivatives and their therapeutic use | SANOFI AVENTIS (FR) | 2009-02-25 | — | — | CN | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | DGAT1 3120/4885CA1 4881/4885CA2 4727/4885 |
| US-10722520-B2 | Heterocyclic compounds and their use in preventing or treating bacterial infections | GNE, CFTR, FPR1 | DGAT1 1457/4885CA1 3719/4885CA2 1725/4885 |
| US-20190224210-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS | GNE, CFTR, FPR1 | DGAT1 1457/4885CA1 3719/4885CA2 1725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.